Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Psoriatic Arthritis AND Psoriasis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    192 result(s) found for: Psoriatic Arthritis AND Psoriasis. Displaying page 4 of 10.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2007-004241-15 Sponsor Protocol Number: IM101-158 Start Date*: 2007-12-21
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Phase IIB, Multi-Dose, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo in the Treatment of Psoriatic Arthritis. A...
    Medical condition: Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Prematurely Ended) NL (Completed) ES (Prematurely Ended) GB (Prematurely Ended) BE (Completed) IT (Prematurely Ended)
    Trial results: Removed from public view
    EudraCT Number: 2009-012424-87 Sponsor Protocol Number: 2104091 Start Date*: 2009-11-26
    Sponsor Name:Imperial College London South Kensington London
    Full Title: T cells and TNF: The impct of TNF blockade on effector T cell populations in rheumatoid arthritis and other conditions treated with anti-TNF-alpha agents.
    Medical condition: Rheumatoid arthritis Psoriatic arthritis Ankylosing spondylitis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10039073 Rheumatoid arthritis LLT
    12.0 10037160 Psoriatic arthritis LLT
    12.0 10002556 Ankylosing spondylitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-002394-38 Sponsor Protocol Number: CAIN457F2354 Start Date*: 2016-05-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 52-week, multicenter study to assess the time course of response to secukinumab on joint inflammation using Power Doppler ultrasonography in patients with active psoriatic arthritis
    Medical condition: Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) ES (Completed) HU (Completed) BE (Completed) NO (Completed) FR (Completed) AT (Completed) NL (Completed) CZ (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000242-30 Sponsor Protocol Number: CNTO148PSA3001 Start Date*: 2014-12-29
    Sponsor Name:Janssen Biologics, BV
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects with Active Psoriatic Arthritis
    Medical condition: Psoriatic Arthritis (PsA)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed) ES (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-000699-32 Sponsor Protocol Number: EU-0208/REMICADEPSO1006 Start Date*: 2011-09-28
    Sponsor Name:UZ KULeuven, service of Rheumatology
    Full Title: Nail involvement in psoriatic arthritis: a cross-sectional and observational prospective study.
    Medical condition: psoriatic artritis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10028395 - Musculoskeletal and connective tissue disorders 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004798-17 Sponsor Protocol Number: CAIN457F2301T Start Date*: 2015-05-26
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: Evaluation of inflammatory and structural joint damage in patients with psoriasis and psoriatic arthritis treated with secukinumab: A phase 2, single arm, single centre mode of action study (Psoria...
    Medical condition: Psoriasis or prosiatric arthritis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    18.1 10040785 - Skin and subcutaneous tissue disorders 10037154 Psoriasis aggravated LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000545-52 Sponsor Protocol Number: GLPG0634-CL-225 Start Date*: 2017-10-06
    Sponsor Name:Galapagos Nv
    Full Title: A multicenter, open-label, long-term extension safety and efficacy study of filgotinib treatment in subjects with moderately to severely active psoriatic arthritis
    Medical condition: Psoriatic arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Prematurely Ended) BG (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001163-37 Sponsor Protocol Number: CNTO1959PSA3001 Start Date*: 2017-07-25
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects with Active Psoriatic Arthritis i...
    Medical condition: Active Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) ES (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-002004-39 Sponsor Protocol Number: BAT-2506-002-CR Start Date*: 2021-04-23
    Sponsor Name:Bio-Thera Solutions, Ltd.
    Full Title: A Multicenter, Double-blind, Randomized, Parallel-group Study to Compare the Efficacy and Safety of BAT2506 Versus Simponi® in Participants with Active Psoriatic Arthritis
    Medical condition: Psoriatic arthritis (PsA)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2020-005099-36 Sponsor Protocol Number: IM011-055 Start Date*: 2021-08-03
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: POETYK PsA-2 (055) - A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Participants with Active Psoriatic Arthritis (Ps...
    Medical condition: Active Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) IT (Completed) BE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001085-42 Sponsor Protocol Number: POISE Start Date*: 2018-06-18
    Sponsor Name:University of Oxford
    Full Title: Clinical effectiveness of symptomatic therapy compared to standard step up care for the treatment of low impact psoriatic oligoarthritis: a 2 arm parallel group feasibility study.
    Medical condition: Psoriatic Arthritis (PsA) is an inflammatory arthritis. PsA is a highly heterogenous disease with a proportion of participants having mild non-progressive disease. Well validated prognostic factor...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2013-001368-46 Sponsor Protocol Number: A3921125 Start Date*: 2013-10-23
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONS...
    Medical condition: Psoriatic arthritis (PsA)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) ES (Completed) SK (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2022-000847-62 Sponsor Protocol Number: ATI-450-PsA-201 Start Date*: 2022-10-17
    Sponsor Name:Aclaris Therapeutics, Inc.
    Full Title: A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zunsemetinib vs Placebo in Patients with ...
    Medical condition: Moderate-to-Severe Active Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-002960-29 Sponsor Protocol Number: 79048 Start Date*: 2020-02-18
    Sponsor Name:Merete Haedersdal [Bispebjerg Hospital]
    Full Title: Assessing the efficacy of image-guided laser-assisted Enstilar® delivery for treatment of psoriatic nails - a proof-of-concept, single-center, prospective, open-label, randomized, clinical trial wi...
    Medical condition: Nail psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10065874 Psoriatic conditions HLT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10037162 Psoriatic arthropathy PT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10028703 Nail psoriasis PT
    22.0 10040785 - Skin and subcutaneous tissue disorders 10028691 Nail discoloration LLT
    21.1 10040785 - Skin and subcutaneous tissue disorders 10006373 Brittle nails LLT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10028689 Nail changes LLT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10028690 Nail deformation LLT
    21.1 10040785 - Skin and subcutaneous tissue disorders 10049281 Nail loss LLT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10064253 Nail pain LLT
    21.1 10040785 - Skin and subcutaneous tissue disorders 10064768 Nail growth increased LLT
    21.1 10040785 - Skin and subcutaneous tissue disorders 10065260 Splitting nails LLT
    21.0 10040785 - Skin and subcutaneous tissue disorders 10069831 Broken nails LLT
    21.0 10040785 - Skin and subcutaneous tissue disorders 10072708 Nail bed hemorrhage LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-000955-11 Sponsor Protocol Number: TILD-19-07 Start Date*: 2021-04-23
    Sponsor Name:Sun Pharmaceutical industries Ltd
    Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experienced Subjects with Active Psoriatic Arthritis I (INSPIRE 1)
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) EE (Trial now transitioned) SK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004241-16 Sponsor Protocol Number: B7931030 Start Date*: 2019-08-02
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PF-06700841 TO EVALUATE THE EFFICACY AT 16 WEEKS AND TO EVALUATE THE SAFETY AND EFFICACY UP TO 1 YEAR IN SUBJECTS WITH ACTIVE PSORI...
    Medical condition: Psoriatic arthritis (PsA)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed) CZ (Completed) BG (Completed) LT (Completed) EE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-002628-27 Sponsor Protocol Number: CAIN457A2206 Start Date*: 2009-01-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Randomized, double-blind, placebo-controlled, multi-center, proof-of-concept study to assess the efficacy of AIN457 in patients with psoriatic arthritis
    Medical condition: Psoriatic arthritis (PsA), which belongs to seronegative spondyloarthropathies (SpA).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002465-22 Sponsor Protocol Number: M16-011 Start Date*: 2018-12-11
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3, Randomized, Double-Blind, Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or intolerance to at Leas...
    Medical condition: Psoriatic Arthritis.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Trial now transitioned) NL (Ongoing) LT (Trial now transitioned) PT (Trial now transitioned) LV (Trial now transitioned) DE (Trial now transitioned) GR (Trial now transitioned) FI (Trial now transitioned) BE (Trial now transitioned) SI (Completed) SK (Trial now transitioned) HR (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-003056-14 Sponsor Protocol Number: VTX958-203 Start Date*: 2023-05-03
    Sponsor Name:Ventyx Biosciences, Inc
    Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Patients with Active Psoriatic Arthritis
    Medical condition: Active Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) HU (Completed) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-019941-24 Sponsor Protocol Number: CC-10004-PSA-004 Start Date*: 2010-12-01
    Sponsor Name:Celgene Corporation
    Full Title: A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two doses of Apremilast (CC-10004) in subjects with active psoriatic arthritis and...
    Medical condition: Psoriatic arthritis, an inflammatory arthritis that, depending on the method of ascertainment, occurs in 6 to 39% of patients with psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) SK (Completed) FI (Completed) GB (Completed) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 08:33:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA